Almirall, a CataloniaBio & HealthTech member, has announced the agreement to acquire Bioniz Therapeutics, Inc. based in Irvine (California, US) for €55 million.
Bioniz is a clinical stage biopharmaceutical company that develops first-in-class peptide treatments that selectively inhibit multiple cytokines to treat immuno-inflammatory diseases and T-cell malignancies.
Bioniz' lead product candidate, BNZ-1, has completed Phase I Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) clinical trials and is currently in Phase I/IIa clinical development in Cutaneous T-cell Lymphoma (CTCL).
Bhushan Hardas, Chief Scientific Officer of Almirall, commented that “this agreement is a big step forward for us in our objective of becoming a leader in Onco-dermatology and Immuno-dermatology."
You may also be interested in:
Photo: Pharmaceutical Plant in Sant Andreu de la Barca (Barcelona) - © Almirall
Comments